Clinical trials · Houston, TX
Refractory High Risk Myelodysplastic Syndrome clinical trials in Houston
We’re tracking 27 recruiting refractory high risk myelodysplastic syndrome studies with a site in or near Houston — including Phase 1, Phase 1/Phase 2 and Phase 2/Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Houston
- NCT05211570RecruitingPhase 1/Phase 2
Study drug AB8939 for AML after prior treatments
This Phase 1/2 study tests AB8939 in people with acute myeloid leukemia (AML) whose disease has come back or did not respond to earlier treatment. It may help researchers find a safe dose and learn whether the treatment can control the leukemia.
Houston, TexasAges 18 years+ - NCT04771572RecruitingPhase 1
Oral drug LP-118 for relapsed blood cancers
This Phase 1 study tests an oral (by mouth) drug called LP-118 in people whose blood cancers have returned or did not respond to prior treatment. The goal is to find a safe dose and see whether it can shrink or control the cancer.
Houston, TexasAges 13 years+ - NCT04708054RecruitingPhase 2/Phase 3
Venetoclax with busulfan chemo for high-risk AML or MDS
This study tests whether adding venetoclax to a specific busulfan-based chemotherapy plan improves outcomes for people with high-risk AML or MDS. It mainly targets patients whose leukemia/marrow disease still has high-risk features or measurable disease after initial treatment.
Houston, TexasAges 18–70
Hear when a new Refractory High Risk Myelodysplastic Syndrome trial opens near Houston, TX
We’ll email you when one opens near Houston, TX — at most once a week, no account needed, unsubscribe anytime.
Where these studies are running near Houston
Institutions with a site for the recruiting refractory high risk myelodysplastic syndrome studies listed above.
- The University of Texas MD Anderson Cancer Center · 3 studies
What taking part in a refractory high risk myelodysplastic syndrome study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting refractory high risk myelodysplastic syndrome studies in Texas.
Common questions
- Are there refractory high risk myelodysplastic syndrome clinical trials near Houston?
- Yes. We're currently tracking 27 recruiting refractory high risk myelodysplastic syndrome studies with a site near Houston, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a refractory high risk myelodysplastic syndrome study near Houston?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Houston to take part?
- Not necessarily. These studies have a site near Houston, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a refractory high risk myelodysplastic syndrome trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New refractory high risk myelodysplastic syndrome studies open near Houston regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.